Can you get weight loss injections for free on the NHS?

What the official guidance actually says about free access

NICE published its recommendation for tirzepatide in December 2024 (updated September 2025), setting out the conditions under which the NHS in England should fund it. NICE technology appraisal TA1026 specifies adults with a BMI of 35 or above plus at least one weight-related comorbidity from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. For semaglutide, NICE TA875 adds a further condition: it should be used for a maximum of two years and only within a specialist weight management service with multidisciplinary support.

These are not soft suggestions. A prescriber cannot simply decide to fund either medicine on the NHS outside those conditions. The guidance exists because both trial programmes produced striking results (tirzepatide reduced average body weight by around 20–21% over 72 weeks in clinical trials, semaglutide around 15% at the 2.4mg maintenance dose) but translating that evidence into a funded service takes time and infrastructure. The NHS is rolling access out in deliberate stages rather than opening the doors at once.

Scotland, Wales and Northern Ireland commission healthcare independently, so their thresholds and timelines differ. If you are outside England, the NHS Inform Scotland page on diabetes and weight-loss medication covers the devolved position for Scottish readers.

The NHS rollout timetable in England, where things stand

NHS England is introducing tirzepatide through GP practices in a series of cohorts rather than a single launch. From June 2025, GPs could prescribe it for patients with a BMI of 40 or above who have four or more of the five qualifying conditions. Cohort 2, covering BMI 35–39.9 with four or more conditions, was activated on 23 June 2026. A further expansion to BMI 40-plus with three qualifying conditions is expected around March 2027.

Even within those cohorts, GP participation is optional under the 2026/27 contract terms, so some practices are prescribing now and others are not. Every NHS patient is also expected to take part in structured diet and activity support alongside the medicine. Meeting the clinical criteria is the floor, not a guarantee of a prescription at your next appointment.

If you want to understand the process from your GP's perspective, our page on getting weight loss injections from your GP covers the conversation to have and what supporting information helps. For a broader picture of how many people are currently on treatment, the uptake figures across the UK make for useful context.

If you do not yet qualify for free NHS treatment

A significant proportion of people who would benefit clinically fall outside the current NHS cohorts, or live in areas where GP participation is patchy, or simply cannot afford to wait while phases roll out slowly. For them, private treatment through a regulated UK pharmacy is a real option, provided they still go through a proper clinical assessment.

The cost of weight loss injections privately varies by dose and provider. Since Eli Lilly adjusted Mounjaro's UK list price in September 2025, typical private prices have ranged roughly £149–£375 per month by dose. That is a meaningful outlay, and it is worth understanding what a legitimate price includes: the prescriber's assessment, the prescription itself, and in some cases delivery and aftercare. Prices that look dramatically lower than that range warrant scrutiny.

At nume, our prescribers review every consultation personally the same day, a real clinician reads your answers, not a scoring algorithm. If treatment is clinically suitable and you order before noon on a working day, your medicine is dispatched that afternoon and arrives the next working day via tracked DPD delivery, in plain packaging. One transparent price covers the consultation, prescription, medicine, and delivery. No subscription, no auto-renewal; each repeat order is clinically reviewed again before it goes out. You can verify our pharmacy on the GPhC register at registration number 9012878.

If you are unsure whether you currently qualify on the NHS, or whether private treatment fits your circumstances, the eligibility criteria for weight loss injections lays out both routes side by side. The step-by-step guide to getting started covers both the NHS pathway and the private one.

A note on timing (and keeping expectations realistic

If you are hoping to start treatment around a particular point) before a long holiday, or once payday lines up, private treatment has a clearer timeline than the NHS route, where referral waits and service capacity are genuinely unpredictable right now. That predictability is one practical reason some people choose the private route even when they might eventually qualify for NHS funding.

Either way, the medicine is the same clinically regulated product from the same licensed UK supply chain. What differs is who pays, who reviews your case, and how long you wait. Both routes require a prescriber to assess your individual health picture; neither offers the medicine over the counter or without clinical oversight. Anything that does should be treated as a serious warning sign, the MHRA has seized large quantities of fake weight-loss pens from unverified online sellers and warned that some have contained dangerous substances.

If you want to explore whether private treatment is suitable for you, speak to our prescribers through a free consultation. There is no obligation, and the clinical review covers your full health picture before anything is prescribed.